Prosecution Insights
Last updated: November 20, 2026

Bong-Sook Baek, USPTO Patent Examiner

Listed by the USPTO as BAEK, BONG-SOOK

Tech Center 1600 • Art Units: 1611 1612 1614 1615 1616 1619 1621 1624 1627 1629

This examiner grants 42% of resolved cases

Analysis

BAEK, BONG-SOOK is assigned to technology center 1600 and art unit 1611. The profile covers 932 resolved cases, with a 41.7% allowance rate and a median of 1143 days to allowance. The 69.9% interview lift is substantial and indicates that interviews are a particularly important feature of this prosecution record.

The listed companies are Scai Therapeutics, Genentech, and Beam Therapeutics. The listed firms are SUGHRUE MION, Acuity Law Group, and AKERMAN. Counsel should plan for a challenging allowance environment while giving serious attention to examiner interviews. The combination of the allowance result and interview association supports preparing detailed, technically focused discussions before adopting amendments that could constrain future claim scope.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

41.7%
Allow Rate
-18.3% vs TC avg
988
Total Applications
+69.9%
Interview Lift
1143
Avg Prosecution Days
Based on 932 resolved cases, 2023–2026

Rejection Statute Breakdown

2.2%
§101 Eligibility
17.5%
§102 Novelty
37.4%
§103 Obviousness
23.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18801886 Cardiosafe Antidiabetic Therapy Final Rejection Boehringer Ingelheim International GmbH
18012099 AMELIORATING AGENT OR PROPHYLACTIC AGENT FOR MUSCLE WEAKNESS SYMPTOM IN DISEASE OR SYNDROME ASSOCIATED WITH METABOLIC DISORDER Non-Final OA Toray Industries, Inc.
18741056 MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS Non-Final OA The Johns Hopkins University
16935005 USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY Final Rejection Jazz Pharmaceuticals Research UK Limited
19088104 COMPOSITION FOR REDUCING AMOUNT OF REACTIVE OXYGEN Non-Final OA KANEKA CORPORATION
18276929 CORONAL PROTEIN-COATED NANOPARTICLES AND USES THEREOF Final Rejection UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
19105710 CARBONATED JELLY DRINK Non-Final OA OTSUKA PHARMACEUTICAL FACTORY, INC.
18907757 COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER Non-Final OA OTSUKA PHARMACEUTICAL CO., LTD.
18696604 HAIR CARE COMPOSITIONS, METHOD FOR PROVIDING IMPROVED CURLS DEFINITION TO THE HAIR AND METHOD OF TREATING HAIR Final Rejection L'OREAL
18777264 COMPOSITIONS AND METHODS FOR RESHAPING KERATIN-RICH SUBSTRATES AND FORMING ADHERENT FLEXIBLE FILMS Non-Final OA Gelest, Inc.
19040204 METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT Final Rejection Alto Neuroscience, Inc.
18700760 ANTIMICROBIAL COMPOSITION AND METHOD FOR MAKING THE SAME Final Rejection WACKER CHEMIE AG
18024679 COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING BRAIN DAMAGE AND MILD COGNITIVE IMPAIRMENT COMPRISING GLUTAMINE AS EFFECTIVE COMPONENT Non-Final OA INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
18746791 NANOMATERIALS COMPRISING TETRAVALENT LIPID COMPOUNDS Non-Final OA Beam Therapeutics Inc.
18005137 USE OF ALVERINE OR ITS DERIVATIVES FOR THE TREATMENT OF MITOCHONDRIAL DISEASES OR DYSFUNCTION ASSOCIATED WITH MITOCHONDRIAL COMPLEX I DEFICIENCIES Non-Final OA UNIVERSITE DE BORDEAUX
18639661 COMPOSITIONS FOR AND METHODS OF INHIBITING SARS-COV-2 INFECTION Non-Final OA Texas Southern University
17753654 METHOD FOR PREVENTING PRECIPITATION OF INJECTABLE SOLUTION CONTAINING p-BORONOPHENYLALANINE Final Rejection Stella Pharma Corporation
18289726 NASAL SLEEP FORMULATION Final Rejection CS MEDICA A/S

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Bong-Sook Baek's allowance rate?

41.7% of resolved applications examined by Bong-Sook Baek were allowed (932 resolved cases), compared with 35.4% across Art Unit 1611 over the last five years.

Does an interview help with examiner Bong-Sook Baek?

This examiner's interview lift is +69.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Bong-Sook Baek take to allow a patent?

Applications allowed by Bong-Sook Baek took 1,143 days on average from filing to allowance.

Which art unit does examiner Bong-Sook Baek work in?

Bong-Sook Baek examines applications in Art Unit 1611 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month